Ovarian function and disease activity in patients with systemic lupus erythematosus

Menstrual cycle disturbances frequently occur during the onset or in exacerbation periods of systemic lupus erythematosus (SLE), suggesting a possible relationship. The aim of the study is to assess the ovarian function in SLE patients with active disease before the treatment with high doses of gluc...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2008-05, Vol.26 (3), p.436
Main Authors: Shabanova, S S, Ananieva, L P, Alekberova, Z S, Guzov, I I
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antirheumatic Agents - therapeutic use
Case-Control Studies
Cyclophosphamide - therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Estrogens - blood
Female
Follicle Stimulating Hormone - blood
Glucocorticoids - therapeutic use
Humans
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - physiopathology
Luteinizing Hormone - blood
Menarche - physiology
Menstruation - physiology
Middle Aged
Oligomenorrhea - blood
Oligomenorrhea - epidemiology
Oligomenorrhea - physiopathology
Ovary - physiopathology
Prolactin - blood
Risk Factors
Severity of Illness Index
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Menstrual cycle disturbances frequently occur during the onset or in exacerbation periods of systemic lupus erythematosus (SLE), suggesting a possible relationship. The aim of the study is to assess the ovarian function in SLE patients with active disease before the treatment with high doses of glucocorticoids (GC) and cytotoxic agents. We evaluated 94 female SLE patients (mean age of 29.2+/-7.0 years). The mean SLEDAI score was 11.4+/-8.1. Seventy-nine patients had a current use of GC with a median dose of 10 mg/day (8-15). The other 15 patients were untreated. After examination and blood sample collection 40% of the patients were treated and high doses of GC (>30 mg/day); 68% from this group of patients were treated GC in combination with cyclophosphamide (CYC). Forty healthy women with the same mean age were evaluated as controls. A careful gynecological history and a gynecological examination were carried out in patients and controls. Hormonal serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, estradiol (E2) and progesterone in SLE patients and controls were measured by enzyme-linked immunosorbent assay (ELISA). Menstrual cycle disorders with oligomenorrhea as dominant aspect were observed in 54% of SLE patients. The hormonal studies showed decreased progesterone level in 52% of patients, reduced E2 concentration in 25% of patients; increased levels of LH, FSH and prolactin were observed with the lower frequency (13%, 9%, 10% respectively). Menstrual cycle disorders and the hormonal unbalance such as decreased progesterone level and hyperprolactinemia were found related significantly to high SLEDAI score (p
ISSN:0392-856X